Skip to content

Comment on FDA approves first in class targeted therapy for metastatic pancreatic cancerparent

Comments

From the post-mortem.

"The biggest bottleneck in the clinical trial system is recruitment and retention. It’s hard to get patients, and it’s hard to keep them."

Yes, this was part of the Chinese reforms of 2016 that I mentioned in the next comment. I don't get why people just downvote things without learning more about them.

Like China = always evil? No, they are an authoritarian system, but that does not mean that every single idea coming from them is bad or evil.

AboutSource Built by g1lg1l

Hackerly is an independent reader for Hacker News, built on the public HN API. Not affiliated with Y Combinator.